Association between N363S and BcLI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Treatment-Related Side Effects in Acute Lymphoblastic Leukemia Patients: A Study from Khyber Pakhtunkhwa, Pakistan
DOI:
https://doi.org/10.70749/ijbr.v3i3.854Keywords:
Genetic Variation, Glucocorticoids, Polymorphism, Leukemia, PakistanAbstract
Objectives: To evaluate the association between N363S and BcLI polymorphisms of the NR3C1 gene and glucocorticoid treatment-related side effects in acute lymphoblastic leukemia patients. Study design and setting: A Cross-sectional study was conducted at the Department of Hematology, Hayatabad Medical Complex, Peshawar from January 2023 to December 2023. Methods: A total of 88 patients aging between 6 months to 25 years newly diagnosed with acute lymphoblastic leukemia were included in this study. Patients received induction chemotherapy, which included a glucocorticoid treatment regimen consisting of dexamethasone, administered at a dose of 6 mg/m² daily, which was continued for a duration of 28 days within the induction phase consisting of 6 weeks. Metabolic and biochemical parameters were measured at baseline and after completing the 28-day dexamethasone treatment course. Primary outcomes included evaluating the clinical manifestations of glucocorticoid treatment related side effects and association between polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and these adverse effects. Results: The mean age of patients in this study was 12.56 ± 5.1 years with an age range of 6 months to 25 years. The sample consisted of 70.5% males and 29.5% females. Glucocorticoid treatment significantly increased hyperglycemia (p<0.001), hypertension (p=0.002), hypertriglyceridemia (p<0.001), dyslipidemia (p<0.001), elevated ALT (p=0.034), elevated ALP (p<0.001), and Cushingoid features (p<0.001). In N363S genotype analysis, hyperglycemia (p=0.03) and hypertension (p=0.02) showed significant associations, while BcLI genotype showed no significant associations with any parameter. Conclusion: Genetic screening for NR3C1 polymorphism can enable personalized glucocorticoid therapy in the patients of Acute Lymphoblastic Leukemia to minimize treatment-related metabolic complications.
Downloads
References
Puckett, Y., & Chan, O. (2022). Acute Lymphocytic Leukemia (ALL). Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459149/
Terwilliger, T., & Abdul-Hay, M. (2017). Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer Journal, 7(6), e577-e577. https://doi.org/10.1038/bcj.2017.53
Reichardt, S. D., Amouret, A., Muzzi, C., Vettorazzi, S., Tuckermann, J. P., Lühder, F., & Reichardt, H. M. (2021). The role of glucocorticoids in inflammatory diseases. Cells, 10(11), 2921. https://doi.org/10.3390/cells10112921
Pufall, M. A. (2015). Glucocorticoids and cancer. Advances in Experimental Medicine and Biology, 315-333. https://doi.org/10.1007/978-1-4939-2895-8_14
Buonaiuto, R., Neola, G., Cecere, S. C., Caltavituro, A., Cefaliello, A., Pietroluongo, E., De Placido, P., Giuliano, M., Arpino, G., & De Angelis, C. (2023). Glucocorticoid receptor and ovarian cancer: From biology to therapeutic intervention. Biomolecules, 13(4), 653. https://doi.org/10.3390/biom13040653
Van Hulst, A. M., Peersmann, S. H., Van den Akker, E. L., Schoonmade, L. J., Van den Heuvel‐Eibrink, M. M., Grootenhuis, M. A., & Van Litsenburg, R. R. (2021). Risk factors for steroid‐induced adverse psychological reactions and sleep problems in pediatric acute lymphoblastic leukemia: A systematic review. Psycho-Oncology, 30(7), 1009-1028. https://doi.org/10.1002/pon.5654
Faggiano, A., Mazzilli, R., Natalicchio, A., Adinolfi, V., Argentiero, A., Danesi, R., D’Oronzo, S., Fogli, S., Gallo, M., Giuffrida, D., Gori, S., Montagnani, M., Ragni, A., Renzelli, V., Russo, A., Silvestris, N., Franchina, T., Tuveri, E., Cinieri, S., … Zatelli, M. C. (2022). Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian association of medical oncology (AIOM)/ Italian association of medical diabetologists (AMD)/ Italian society of endocrinology (SIE)/ Italian society of pharmacology (SIF) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 180, 103826. https://doi.org/10.1016/j.critrevonc.2022.103826
Kaminski, H. J., & Denk, J. (2022). Corticosteroid treatment-resistance in myasthenia gravis. Frontiers in Neurology, 13. https://doi.org/10.3389/fneur.2022.886625
Pac, M., Krata, N., Moszczuk, B., Wyczałkowska-Tomasik, A., Kaleta, B., Foroncewicz, B., Rudnicki, W., Pączek, L., & Mucha, K. (2021). NR3C1 glucocorticoid receptor gene polymorphisms are associated with membranous and IgA Nephropathies. Cells, 10(11), 3186. https://doi.org/10.3390/cells10113186
Shahid, S., Shakeel, M., Siddiqui, S., Ahmed, S., Sohail, M., Khan, I. A., Abid, A., & Shamsi, T. (2020). Novel genetic variations in acute myeloid leukemia in Pakistani population. Frontiers in Genetics, 11. https://doi.org/10.3389/fgene.2020.00560
Tsai, M., Huang, H., Chou, Y., Cheng, C., Chen, J., & Lin, S. (2015). Risk factors for hyperglycemia during chemotherapy for acute lymphoblastic leukemia among Taiwanese children. Pediatrics & Neonatology, 56(5), 339-345. https://doi.org/10.1016/j.pedneo.2015.01.008
Goulden, N. J., Kirkwood, A. A., Moppett, J., Samarasinghe, S., Lawson, S., Rowntree, C., ... & Vora, A. (2017). UKALL 2011: randomised trial investigating a short induction dexamethasone schedule for children and young adults with acute lymphoblastic leukaemia. Blood, 130, 141. https://doi.org/10.1182/blood.V130.Suppl_1.141.141
Pourhassan, H., Murphy, L., & Aldoss, I. (2024). Glucocorticoid therapy in acute lymphoblastic leukemia: Navigating short-term and long-term effects and optimal regimen selection. Current Hematologic Malignancy Reports, 19(4), 175-185. https://doi.org/10.1007/s11899-024-00735-w
Namazi, S., Zareifar, S., Monabati, A., Ansari, S., & Karimzadeh, I. (2011). Evaluating the effect of 3 glucocorticoid receptor gene polymorphisms on risk of relapse in 100 Iranian children with acute lymphoblastic leukemia: A case-control study. Clinical Therapeutics, 33(3), 280-290. https://doi.org/10.1016/j.clinthera.2011.03.004
Eipel, O., Hegyi, M., Csordás, K., Németh, K., Luczay, A., Török, D., Csóka, M., Erdélyi, D., & Kovács, G. (2016). Some GCR polymorphisms (N363S, ER22/23EK, and bcl-1) may influence steroid-induced Toxicities and survival rates in children with ALL. Journal of Pediatric Hematology/Oncology, 38(5), 334-340. https://doi.org/10.1097/mph.0000000000000535
ElFayoumi, R. I., Hagras, M. M., Abozenadaha, A., Gari, M., Abosoudah, I., Shinawi, T., Mirza, T., & Bawazir, W. (2019). The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia. Pharmacological Reports, 71(1), 90-95. https://doi.org/10.1016/j.pharep.2018.09.010
Kaymak Cihan, M., Karabulut, H. G., Yürür Kutlay, N., Ilgın Ruhi, H., Tükün, A., & Olcay, L. (2017). Association between N363S and BclI polymorphisms of the glucocorticoid receptor gene (NR3C1) and glucocorticoid side effects during childhood acute lymphoblastic leukemia treatment. Turkish Journal of Hematology, 151-158. https://doi.org/10.4274/tjh.2016.0253
Reimondo, G., Chiodini, I., Puglisi, S., Pia, A., Morelli, V., Kastelan, D., Cannavo, S., Berchialla, P., Giachino, D., Perotti, P., Cuccurullo, A., Paccotti, P., Beck-Peccoz, P., De Marchi, M., & Terzolo, M. (2016). Analysis of bcli, n363s and er22/23ek polymorphisms of the glucocorticoid receptor gene in adrenal Incidentalomas. PLOS ONE, 11(9), e0162437. https://doi.org/10.1371/journal.pone.0162437
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
